Maze Therapeutics has finalized the pricing for a registered offering of 5.54 million shares. The move is expected to raise approximately $150 million in gross proceeds.
- Offering consists of 5.54 million shares
- Price set at $23.50 per share
- Total gross proceeds estimated at $150 million
- Includes pre-funded warrants for select investors
- Capital intended to support corporate objectives
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.